Sub Banner Image

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data

Market Impact

Vandana Singh

·

September 5, 2025

·

Benzinga

BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.